Pro Medicus Limited (OTCMKTS:PMCUF – Get Free Report) gapped up before the market opened on Wednesday. The stock had previously closed at $129.76, but opened at $137.0250. Pro Medicus shares last traded at $137.0250, with a volume of 25 shares.
Analysts Set New Price Targets
Separately, Jefferies Financial Group cut Pro Medicus from a “buy” rating to a “hold” rating in a research report on Wednesday, July 8th. One investment analyst has rated the stock with a Hold rating. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $155.00.
Get Our Latest Stock Analysis on PMCUF
Pro Medicus Stock Performance
The stock has a 50 day moving average of $120.93 and a 200-day moving average of $110.98.
About Pro Medicus
Pro Medicus Limited is an Australian medical technology company that develops software for medical imaging and healthcare organizations. Its solutions are designed to help hospitals, radiology practices and other providers store, manage, view and distribute medical images and related clinical information.
The company’s principal platform is Visage 7, an enterprise imaging system developed and commercialized through its wholly owned subsidiary, Visage Imaging. The platform supports the review of diagnostic studies such as computed tomography, magnetic resonance imaging and other medical images, with an emphasis on enterprise-wide access, workflow efficiency and advanced visualization.
Founded in 1983 and headquartered in Melbourne, Australia, Pro Medicus serves healthcare customers in Australia, North America and Europe.
Further Reading
- Five stocks we like better than Pro Medicus
- Amazon’s Record Margins Couldn’t Stop the Sell-Off—Here’s Why
- DoorDash’s $17 Billion Bet on Instacart Faces a Long Regulatory Road Ahead
- FTC Puts A Wrinkle In the Cintas and UniFirst Merger
- Breaching the Valuation: The Real Reason Fortinet Dropped
Receive News & Ratings for Pro Medicus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pro Medicus and related companies with MarketBeat.com's FREE daily email newsletter.
